Pre- and postsynaptic type-1 cannabinoid receptors control the alterations of glutamate transmission in experimental autoimmune encephalomyelitis

Neuropharmacology

Volumn 79, Issue , 2014, Pages 567-572

  Musella, Alessandra ^a,b   Sepman, Helena ^a,b   Mandolesi, Georgia ^a   Gentile, Antonietta ^a,b   Fresegna, Diego ^a   Haji, Nabila ^a   Conrad, Andrea ^c   Lutz, Beat ^c   Maccarrone, Mauro ^a,d   Centonze, Diego ^a,b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

EAE; EPSC; Excitotoxicity; GABA; Glutamate; Multiple sclerosis; Striatum

Indexed keywords

4 AMINOBUTYRIC ACID; CANNABINOID 1 RECEPTOR; GLUTAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; EXCITATORY POSTSYNAPTIC POTENTIAL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; GABAERGIC SYSTEM; INFLAMMATION; MOTOR DYSFUNCTION; MOUSE; MULTIPLE SCLEROSIS; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; SYNAPSE; ANIMAL; C57BL MOUSE; DISEASE COURSE; IN VITRO STUDY; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION; SYNAPTOSOME; TIME;

ANIMALS; CORPUS STRIATUM; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; IN VITRO TECHNIQUES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; PRESYNAPTIC TERMINALS; RECEPTOR, CANNABINOID, CB1; SYNAPTIC TRANSMISSION; TIME FACTORS;

EID: 84893464528     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.01.007     Document Type: Article

References (54)

1. A. Arévalo-Martín, J.M. Vela, E. Molina-Holgadom, J. Borrell, and C. Guaza Therapeutic action of cannabinoids in a murine model of multiple sclerosis J. Neurosci. 23 2003 2511 2516 (Pubitemid 36418583)
2. T. Bisogno, and V. Di Marzo Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders CNS Neurol. Disord. Drug. Targets 9 2010 564 573
3. D. Centonze, M. Bari, S. Rossi, C. Prosperetti, R. Furlan, F. Fezza, V. De Chiara, L. Battistini, G. Bernardi, S. Bernardini, G. Martino, and M. Maccarrone The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis Brain 130 2007 2543 2553 (Pubitemid 47511703)
4. D. Centonze, F. Mori, G. Koch, F. Buttari, C. Codecà, S. Rossi, M.T. Cencioni, M. Bari, S. Fiore, G. Bernardi, L. Battistini, and M. Maccarrone Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis Neurol. Sci. 30 2009 531 534
5. D. Centonze, L. Muzio, S. Rossi, R. Furlan, G. Bernardi, and G. Martino The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis Cell. Death Differ. 17 2010 1083 1091
6. V. Chevaleyre, K.A. Takahashi, and P.E. Castillo Endocannabinoid-mediated synaptic plasticity in the CNS Annu. Rev. Neurosci. 29 2006 37 76 (Pubitemid 44476839)
7. F.G. Correa, L. Mestre, F. Docagne, J. Borrell, and C. Guaza The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis Vitam. Horm. 81 2009 207 230
8. J.L. Croxford, and S.D. Miller Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212 J. Clin. Invest. 111 2003 1231 1240 (Pubitemid 36519940)
9. J.L. Croxford, G. Pryce, S.J. Jackson, C. Ledent, G. Giovannoni, R.G. Pertwee, T. Yamamura, and D. Baker Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis J. Neuroimmunol. 193 2008 120 129
10. V. De Chiara, F. Errico, A. Musella, S. Rossi, G. Mataluni, L. Sacchetti, A. Siracusano, M. Castelli, F. Cavasinni, G. Bernardi, A. Usiello, and D. Centonze Voluntary exercise and sucrose consumption enhance cannabinoid CB1 receptor sensitivity in the striatum Neuropsychopharmacology 35 2010 374 387
11. E. de Lago, M. Moreno-Martet, A. Cabranes, J.A. Ramos, and J. Fernández-Ruiz Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects Neuropharmacology 62 2012 2299 2308
12. W.A. Devane, F.A. Dysarz 3rd, M.R. Johnson, L.S. Melvin, and A.C. Howlett Determination and characterization of a cannabinoid receptor in rat brain Mol. Pharmacol. 34 1988 605 613 (Pubitemid 19007296)
13. R.E. Gonsette Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity J. Neurol. Sci. 274 2008 48 53
14. A. Gowran, J. Noonan, and V.A. Campbell The multiplicity of action of cannabinoids: implications for treating neurodegeneration CNS Neurosci. Ther. 17 2011 637 644
15. G. Grasselli, S. Rossi, A. Musella, A. Gentile, S. Loizzo, L. Muzio, C. Di Sanza, F. Errico, G. Musumeci, N. Haji, D. Fresegna, H. Sepman, V. De Chiara, R. Furlan, G. Martino, A. Usiello, G. Mandolesi, and D. Centonze Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis Br. J. Pharmacol. 168 2013 502 517
16. N. Haji, G. Mandolesi, A. Gentile, L. Sacchetti, D. Fresegna, S. Rossi, A. Musella, H. Sepman, C. Motta, V. Studer, V. De Chiara, G. Bernardi, P. Strata, and D. Centonze TNF-α-mediated anxiety in a mouse model of multiple sclerosis Exp. Neurol. 237 2012 296 303
17. T. Harkany, E. Keimpema, K. Barabás, and J. Mulder Endocannabinoid functions controlling neuronal specification during brain development Mol. Cell. Endocrinol. 286 2008 S84 S90
18. M.N. Hill, and B.B. Gorzalka The endocannabinoid system and the treatment of mood and anxiety disorders CNS Neurol. Disord. Drug. Targets 8 2009 451 458
19. A.C. Howlett Reverse pharmacology applied to the cannabinoid receptor Trends Pharmacol. Sci. 11 1990 395 397 (Pubitemid 20344020)
20. Y. Kawaguchi, C.J. Wilson, S.J. Augood, and P.C. Emson Striatal interneurones: chemical, physiological and morphological characterization Trends Neurosci. 18 12 Dec 1995 527 535
21. H. Lassmann, J. van Horssen, and D. Mahad Progressive multiple sclerosis: pathology and pathogenesis Nat. Rev. Neurol. 8 2012 647 656
22. A. Lau, and M. Tymianski Glutamate receptors, neurotoxicity and neurodegeneration Pflugers Arch. 460 2010 525 542
23. D.M. Lovinger Presynaptic modulation by endocannabinoids Handb. Exp. Pharmacol. 184 2008 435 477
24. W.D. Lyman, J.R. Sonett, C.F. Brosnan, R. Elkin, and M.B. Bornstein Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis J. Neuroimmunol. 23 1989 73 81 (Pubitemid 19125801)
25. G. Marsicano, S. Goodenough, K. Monory, H. Hermann, M. Eder, A. Cannich, S.C. Azad, M.G. Cascio, S.O. Gutiérrez, M. van der Stelt, M.L. López-Rodriguez, E. Casanova, G. Schütz, W. Zieglgänsberger, V. Di Marzo, C. Behl, and B. Lutz CB1 cannabinoid receptors and on-demand defense against excitotoxicity Science 302 2003 84 88 (Pubitemid 37210691)
26. G. Marsicano, and B. Lutz Neuromodulatory functions of the endocannabinoid system J. Endocrinol. Invest. 29 2006 27 46
27. F. Massa, G. Mancini, H. Schmidt, F. Steindel, K. Mackie, C. Angioni, S.H. Oliet, G. Geisslinger, and B. Lutz Alterations in the hippocampal endocannabinoid system in diet-induced obese mice J. Neurosci. 30 2010 6273 6281
28. C. Matute Glutamate and ATP signalling in white matter pathology J. Anat. 219 2011 53 64
29. L. Mestre, F. Docagne, F. Correa, F. Loría, M. Hernangómez, J. Borrell, and C. Guaza A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules Mol. Cell. Neurosci. 40 2009 258 266
30. K. Monory, F. Massa, M. Egertová, M. Eder, H. Blaudzun, R. Westenbroek, W. Kelsch, W. Jacob, R. Marsch, M. Ekker, J. Long, J.L. Rubenstein, S. Goebbels, K.A. Nave, M. During, M. Klugmann, B. Wölfel, H.U. Dodt, W. Zieglgänsberger, C.T. Wotjak, K. Mackie, M.R. Elphick, G. Marsicano, and B. Lutz The endocannabinoid system controls key epileptogenic circuits in the hippocampus Neuron 51 2006 455 466 (Pubitemid 44209321)
31. A. Musella, V. De Chiara, S. Rossi, F. Cavasinni, M. Castelli, C. Cantarella, G. Mataluni, G. Bernardi, and D. Centonze Transient receptor potential vanilloid 1 channels control acetylcholine/2-arachidonoylglicerol coupling in the striatum Neuroscience 167 2010 864 871
32. A. Musella, V. De Chiara, S. Rossi, C. Prosperetti, G. Bernardi, M. Maccarrone, and D. Centonze TRPV1 channels facilitate glutamate transmission in the striatum Mol. Cell. Neurosci. 40 2009 89 97
33. G. Musumeci, G. Grasselli, S. Rossi, V. De Chiara, A. Musella, C. Motta, V. Studer, G. Bernardi, N. Haji, H. Sepman, D. Fresegna, M. Maccarrone, G. Mandolesi, and D. Centonze Transient receptor potential vanilloid 1 channels modulate the synaptic effects of TNF-α and of IL-1β in experimental autoimmune encephalomyelitis Neurobiol. Dis. 43 2011 69 77
34. S. Ortega-Gutiérrez, E. Molina-Holgado, A. Arévalo- Martín, F. Correa, A. Viso, M.L. López-Rodríguez, V. Di Marzo, and C. Guaza Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis FASEB J. 19 2005 1338 1340 (Pubitemid 41113742)
35. D. Piomelli The molecular logic of endocannabinoid signalling Nat. Rev. Neurosci. 4 2003 873 884 (Pubitemid 37351427)
36. D. Pitt, P. Werner, and C.S. Raine Glutamate excitotoxicity in a model of multiple sclerosis Nat. Med. 6 2000 67 70 (Pubitemid 30048528)
37. G. Pryce, Z. Ahmed, D.J. Hankey, S.J. Jackson, J.L. Croxford, J.M. Pocock, C. Ledent, A. Petzold, A.J. Thompson, G. Giovannoni, M.L. Cuzner, and D. Baker Cannabinoids inhibit neurodegeneration in models of multiple sclerosis Brain 126 2003 2191 2202 (Pubitemid 37432364)
38. G. Pryce, and D. Baker Emerging properties of cannabinoid medicines in management of multiple sclerosis Trends Neurosci. 28 2005 272 276 (Pubitemid 41556912)
39. S. Rossi, G. Bernardi, and D. Centonze The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis Exp. Neurol. 224 2010 92 102
40. S. Rossi, V. De Chiara, R. Furlan, A. Musella, F. Cavasinni, L. Muzio, G. Bernardi, G. Martino, and D. Centonze Abnormal activity of the Na/Ca exchanger enhances glutamate transmission in experimental autoimmune encephalomyelitis Brain Behav. Immun. 24 2010 1379 1385
41. S. Rossi, R. Furlan, V. De Chiara, A. Musella, T. Lo Giudice, G. Mataluni, F. Cavasinni, C. Cantarella, G. Bernardi, L. Muzio, A. Martorana, G. Martino, and D. Centonze Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis Neurobiol. Dis. 36 2009 51 59
42. S. Rossi, R. Furlan, V. De Chiara, L. Muzio, A. Musella, C. Motta, V. Studer, F. Cavasinni, G. Bernardi, G. Martino, B.F. Cravatt, B. Lutz, M. Maccarrone, and D. Centonze Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis Brain Behav. Immun. 25 2011 1242 1248
43. S. Rossi, C. Motta, V. Studer, F. Barbieri, F. Buttari, A. Bergami, G. Sancesario, S. Bernardini, G. De Angelis, G. Martino, R. Furlan, and D. Centonze Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration Mult. Scler. 2013 (in press)
44. S. Rossi, L. Muzio, V. De Chiara, G. Grasselli, A. Musella, G. Musumeci, G. Mandolesi, R. De Ceglia, S. Maida, E. Biffi, A. Pedrocchi, A. Menegon, G. Bernardi, R. Furlan, G. Martino, and D. Centonze Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis Brain Behav. Immun. 25 2011 947 956
45. S. Rossi, F. Buttari, V. Studer, C. Motta, P. Gravina, M. Castelli, V. Mantovani, V. De Chiara, A. Musella, S. Fiore, S. Masini, G. Bernardi, M. Maccarrone, S. Bernardini, and D. Centonze The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis Mult. Scler. 17 2011 281 288
46. S. Rossi, L. Sacchetti, F. Napolitano, V. De Chiara, C. Motta, V. Studer, A. Musella, F. Barbieri, M. Bari, G. Bernardi, M. Maccarrone, A. Usiello, and D. Centonze Interleukin-1β causes anxiety by interacting with the endocannabinoid system J. Neurosci. 32 2012 13896 13905
47. T. Smith, A. Groom, B. Zhu, and L. Turski Autoimmune encephalomyelitis ameliorated by AMPA antagonists Nat. Med. 6 2000 62 66 (Pubitemid 30048527)
48. R. Srinivasan, N. Sailasuta, R. Hurd, S. Nelson, and D. Pelletier Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T Brain 128 2005 1016 1025 (Pubitemid 40675457)
49. C.W. Vaughan, and M.J. Christie Retrograde signalling by endocannabinoids Handb. Exp. Pharmacol. 168 2005 367 383
50. M. Vercellino, A. Merola, C. Piacentino, B. Votta, E. Capello, G.L. Mancardi, R. Mutani, M.T. Giordana, and P. Cavalla Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage J. Neuropathol. Exp. Neurol. 66 2007 732 739 (Pubitemid 47344252)
51. M. Webb, L. Luo, J.Y. Ma, and C.S. Tham Genetic deletion of fatty acid amide hydrolase results in improved long-term outcome in chronic autoimmune encephalitis Neurosci. Lett. 439 2008 106 110
52. I. Wirguin, R. Mechoulam, A. Breuer, E. Schezen, J. Weidenfeld, and T. Brenner Suppression of experimental autoimmune encephalomyelitis by cannabinoids Immunopharmacology 28 1994 209 214 (Pubitemid 24316897)
53. M. Zhang, B.R. Martin, M.W. Adler, R.J. Razdan, W. Kong, D. Ganea, and R.F. Tuma Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke J. Neuroimmune Pharmacol. 4 2009 249 259
54. P. Zhao, D. Leonoudakis, M.E. Abood, and E.C. Beattie Cannabinoid receptor activation reduces TNFalpha-induced surface localization of AMPAR-type glutamate receptors and excitotoxicity Neuropharmacology 58 2010 551 558